Notably, outcomes for patients with myeloma have been improving dramatically [4,5,6,7,8] with the advent of novel therapies [9], and especially of immunomodulatory agents (IMiDs), proteasome inhibitors (PIs), anti-CD38 antibodies, and B-cell maturation antigen (BCMA)-targeted drugs. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.